Travere Therapeutics, Inc. Insider Trading Activity

Travere Therapeutics (TVTX) reported an insider transaction by a director on 10/31/2025.

Accepted by SEC EDGAR 11/04/2025 - 04:05 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Travere Therapeutics (TVTX) reported an insider transaction by a director on 10/31/2025. The director exercised options for 8,000 shares at $16.33 and 10,000 shares at $17.44, then sold 18,000 shares at a weighted average price of $35.0334 (range $35.00–$35.15) under a Rule 10b5-1(c) trading plan adopted on June 16, 2025.

Following these transactions, the director beneficially owned 55,500 shares directly. The reported stock options were fully vested and exercisable.

Insider Trade Summary

Exercise and Sale: 18,000 shares ($326K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Coughlin Timothy

Role Director

Sold 18,000 shs ($631K)

Approx. gross sale proceeds $631K

Approx. exercise cost $305K

Approx. pre-tax spread $326K

Share of Position Sold 24.5%

Type	Security	Shares	Price	Value
Exercise	Director stock option (right to buy)	8,000	$0.00	$0.00
Exercise	Director stock option (right to buy)	10,000	$0.00	$0.00
Exercise	Common Stock	8,000	$16.33	$131K
Exercise	Common Stock	10,000	$17.44	$174K
Sale	Common Stock	18,000	$35.0334	$631K

Holdings After Transaction: Director stock option (right to buy) — 0 contracts (Direct); Common Stock — 55,500 shares (Direct)

Holdings Before and After: Director stock option (right to buy), 18,000 to 0 contracts (Direct); Common Stock, 55,500 to 55,500 shares (Direct)

Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (3)

1. F1. This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
2. F2. The weighted average sale price for the transaction reported was $35.0334, and the range of prices were between $35.00 and $35.15. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
3. F3. The stock option is fully vested and exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the TVTX director do in the latest Form 4 filing?

On 10/31/2025, the director exercised 18,000 options (8,000 at $16.33 and 10,000 at $17.44) and sold 18,000 shares.

At what price were TVTX shares sold in this insider transaction?

The weighted average sale price was $35.0334, with trades ranging between $35.00 and $35.15.

Was the TVTX sale made under a 10b5-1 plan?

Yes. The sale was made under a Rule 10b5-1(c) plan adopted on June 16, 2025.

How many TVTX shares does the director own after the transactions?

The director beneficially owned 55,500 shares directly after the reported transactions.

Were the TVTX options already vested at exercise?

Yes. The filing states the stock options were fully vested and exercisable.

What types of transactions are reported in this TVTX Form 4?

Option exercises (codes M) for 8,000 and 10,000 shares, and an open-market sale (code S) of 18,000 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coughlin Timothy

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DR., SUITE 300

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/31/2025		M		8,000	A	$16.33	63,500	D
Common Stock	10/31/2025		M		10,000	A	$17.44	73,500	D
Common Stock	10/31/2025		S(1)		18,000	D	$35.0334(2)	55,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director stock option (right to buy)	$16.33	10/31/2025		M			8,000	(3)	05/17/2026	Common Stock	8,000	$0	0	D
Director stock option (right to buy)	$17.44	10/31/2025		M			10,000	(3)	05/16/2027	Common Stock	10,000	$0	0	D

Explanation of Responses:

1. This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

2. The weighted average sale price for the transaction reported was $35.0334, and the range of prices were between $35.00 and $35.15. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

3. The stock option is fully vested and exercisable.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	11/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.